AD Clinical Trials

2 recruiting

AD Trials at a Glance

7,061 actively recruiting trials for ad are listed on ClinicalTrialsFinder across 6 cities in 116 countries. The largest study group is Not Applicable with 2,006 trials, with the heaviest enrollment activity in Houston, New York, and Boston. Lead sponsors running ad studies include National Cancer Institute (NCI), M.D. Anderson Cancer Center, and Mayo Clinic.

Treatments under study

About AD Clinical Trials

Looking for clinical trials for AD? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new AD trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about AD clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 7,061 trials

Recruiting
Phase 2

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell CarcinomaRecurrent Oropharyngeal Squamous Cell CarcinomaRecurrent Hypopharyngeal Squamous Cell Carcinoma+2 more
National Cancer Institute (NCI)188 enrolled177 locationsNCT04671667
Recruiting
Phase 2

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Lung Neuroendocrine NeoplasmAdvanced Lung Neuroendocrine TumorFunctioning Lung Neuroendocrine Tumor+9 more
National Cancer Institute (NCI)70 enrolled29 locationsNCT04665739
Recruiting
Phase 2

Semaglutide Therapy for Alcohol Reduction (STAR)

Alcohol Use DisorderAddiction
National Institute on Drug Abuse (NIDA)67 enrolled1 locationNCT06015893
Recruiting
Phase 2

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8
National Cancer Institute (NCI)111 enrolled134 locationsNCT07061964
Recruiting
Phase 2

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Pancreatic Acinar Cell CarcinomaResectable Pancreatic CarcinomaResectable Pancreatic Adenocarcinoma+4 more
National Cancer Institute (NCI)152 enrolled453 locationsNCT04858334
Recruiting
Phase 2Phase 3

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+13 more
National Cancer Institute (NCI)224 enrolled370 locationsNCT06203600
Recruiting
Phase 1

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc.145 enrolled5 locationsNCT07458347
Recruiting
Phase 1Phase 2

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Advanced or Metastatic Non-small Cell Lung Cancer
AstraZeneca152 enrolled104 locationsNCT06996782
Recruiting

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

Bladder CancerKidney CancerRenal Cancer+2 more
National Cancer Institute (NCI)5,950 enrolled1 locationNCT00026884
Recruiting

Study of New Magnetic Resonance Imaging Methods of the Brain

HealthyHealthy VolunteerAdult+3 more
National Institute of Neurological Disorders and Stroke (NINDS)1,100 enrolled1 locationNCT00004577
Recruiting
Phase 3

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

Low Grade Astrocytoma
National Cancer Institute (NCI)170 enrolled132 locationsNCT04166409
Recruiting
Phase 2Phase 3

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Advanced Extrapulmonary Neuroendocrine CarcinomaMetastatic Extrapulmonary Neuroendocrine CarcinomaRecurrent Extrapulmonary Neuroendocrine Carcinoma+1 more
National Cancer Institute (NCI)189 enrolled244 locationsNCT05058651
Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled579 locationsNCT03866382
Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 2

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Recurrent Lung Non-Small Cell CarcinomaAdvanced Lung Non-Small Cell CarcinomaStage IIIB Lung Non-Small Cell Cancer AJCC v7+1 more
National Cancer Institute (NCI)46 enrolled344 locationsNCT03191149
Recruiting

DESTINY-PANTUMOUR04

Liver CancerEsophageal CancerPancreatic Cancer+24 more
AstraZeneca100 enrolled17 locationsNCT07124000
Recruiting

Apheresis of Patients With Immunodeficiency

LAD-1DOCK8GATA2 Deficancy
National Cancer Institute (NCI)7 enrolled1 locationNCT01212055
Recruiting

Data Collection Study of Pediatric and Adolescent Gynecology Conditions

Disorders of Sex Development (DSD)Pediatric and Adolescent Cancers of the Genital TractReproductive Endocrine Conditions in Puberty+1 more
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)11,000 enrolled1 locationNCT04717349
Recruiting

Inherited Reproductive Disorders

InfertilityHypogonadismAmenorrhea+1 more
National Institute of Environmental Health Sciences (NIEHS)850 enrolled2 locationsNCT01500447
Recruiting
Phase 1

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Recurrent Endometrial CarcinomaRecurrent Ovarian High Grade Serous AdenocarcinomaRecurrent Ovarian Clear Cell Adenocarcinoma+6 more
National Cancer Institute (NCI)65 enrolled14 locationsNCT05950464